Evan Feinberg, Genesis Therapeutics CEO

An­dreessen Horowitz-backed start­up lands $200M for AI-based drug dis­cov­ery

Gen­e­sis Ther­a­peu­tics, a start­up us­ing ar­ti­fi­cial in­tel­li­gence to de­sign small mol­e­cule drugs, has raised $200 mil­lion in Se­ries B fi­nanc­ing — one of the largest rounds …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.